Who
Pablo G. Legorreta
CEO, Chairman of the Board
Company insider
Files Form 4 as: CEO, Chairman of the Board, Royalty Pharma; Director and 10% owner, ProKidney; Director and 10% owner, Epizyme.
In numbers
- Trades disclosed
- 87
- Buys
- 8
- Sells
- 0
- Bought
- $74.6M
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 6 Nov 2019
- Last trade
- 7 Aug 2026
- Last filed
- 7 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Aug 2026filed 7 Aug 2026 | RPRX Royalty Pharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code G | —30,000 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | RPRX Royalty Pharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code G | —30,000 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —65,216 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —65,216 at $0.00 | filing |
| 28 May 2026filed 29 May 2026 | PROK ProKidneyoption or derivative · Biotechnology | SEC FORM 4 Code A | —135,000 at $0.00 | filing |
| 28 May 2026filed 29 May 2026 | PROK ProKidneyoption or derivative · Biotechnology | SEC FORM 4 Code A | —135,000 at $0.00 | filing |
| 6 May 2026filed 8 May 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —143,821 at $0.00 | filing |
| 6 May 2026filed 8 May 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —143,821 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —157,828 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —157,828 at $0.00 | filing |
| 5 Nov 2025filed 7 Nov 2025 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —36,559 at $0.00 | filing |
| 8 Aug 2025filed 8 Aug 2025 | RPRX Royalty Pharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code G | —60,000 at $0.00 | filing |
| 6 Aug 2025filed 8 Aug 2025 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —21,901 at $0.00 | filing |
| 3 Jun 2025filed 5 Jun 2025 | PROK ProKidneyoption or derivative · Biotechnology | SEC FORM 4 Code C | —3,823,996 at $0.00 | filing |
| 3 Jun 2025filed 5 Jun 2025 | PROK ProKidneyoption or derivative · Biotechnology | SEC FORM 4 Code C | —3,823,996 at $0.00 | filing |
| 3 Jun 2025filed 5 Jun 2025 | PROK ProKidneyBiotechnology | SEC FORM 4 Code C | —3,823,996 at $0.00 | filing |
| 3 Jun 2025filed 5 Jun 2025 | PROK ProKidneyBiotechnology | SEC FORM 4 Code J | —3,823,996 at $0.00 | filing |
| 29 May 2025filed 2 Jun 2025 | PROK ProKidneyoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,862 at $0.00 | filing |
| 16 May 2025filed 20 May 2025 | RPRX Royalty Pharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —13,356,742 at $0.00 | filing |
| 16 May 2025filed 20 May 2025 | RPRX Royalty Pharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code J | —857,138 at $0.00 | filing |
News
Royalty Pharma (NASDAQ:RPRX) and Aditxt (NASDAQ:ADTX) Financial ComparisonRPRX · themarketsdaily.com · 18 Oct 2026
0 headlines in the last 90 days name Pablo G. Legorreta; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.